The tweet was deleted by the author.
But we saved everything 🙂.
Beam Therapeutics sponsored and attended the Massachusetts Sickle Cell Association's annual Red Ribbon Gala. The company called the event a great time for the #BeamTeam.
The gala supports programs and services for individuals living with sickle cell disease in Massachusetts. Beam Therapeutics expressed joy in taking part in the event.
View post on X Loading...
BEAM ($26.17) is trading well below the MA-20 ($30.21), MA-50 ($30.75), and MA-200 ($28.10) on D1, indicating persistent bearish momentum in the short, medium, and long term. The Ichimoku Kijun is at $31.47, which stands as immediate resistance above the current price. Near-term support is at the MA-5 ($25.68), with key support at MA-100 ($29.23). Immediate resistance lies at the Ichimoku Kijun ($31.47), while key resistance is set by the MA-50 ($30.75).
On D1, MACD signals continued downward momentum, while ADX remains below 20, suggesting the trend lacks strength. RSI is at 36.5 and CCI at −73.8, both in oversold territory, which is partially echoed by Stoch RSI at 30.8. BBP registers an "oversold" reading with sellers dominating intraday action, consistent with a lack of buyer initiative. Awesome Oscillator does not provide a clear directional bias at this level. Over the past week, BEAM has risen $1.07 (3.65%) from the previous weekly close of $25.10, and the price is positioned in the upper part of the weekly range. Weekly volatility stands at 9.53%. Recent action reflects a recovery from the previous weekly low, but momentum and oscillators diverge: strengthening price contrasts with ongoing bearish signals from most D1 indicators.
Looking ahead, the expected price range for the coming week is $25.70 to $27.00, keeping the outlook realistic based on recent weekly volatility. This corridor is above the 52-week low of $15.60 and still well below the 52-week high of $38.26. The probability of a price increase next week is very low (less than 20%), with a decline remaining more likely given the combined "Sell" forecasts on RSI-W1, MA-50-W1, and MACD-W1. The baseline scenario expects sideways movement between $25.70 and $27.00. A bullish scenario would require a decisive breakout above $27.00 toward key resistance at $30.75. Conversely, a bearish break below $25.70 could open the path toward the short-term support at MA-5, with the risk of returning downward momentum.
Previously it was reported that Beam Therapeutics faced ongoing bearish pressure, with analysts highlighting a prevailing downside bias and consolidation near recent lows. In the current context, traders should carefully monitor for a decisive shift in momentum that could signal either a sustained reversal or extension of the downward trend.